The publications presented on this site may contain investigational and exploratory scientific information about PEGPH20, HYLENEX recombinant (hyaluronidase human injection), ENHANZE ® Drug Delivery Technology and other products related to co-formulation. No conclusions of safety or efficacy should be drawn in the absence of or prior to FDA approval.

ENHANZE^® Drug Delivery Technology

Date Title

Locke, K., et al. ENHANZE® Drug Delivery Technology: A Novel Approach to Subcutaneous Administration Using Recombinant Human Hyaluronidase PH20; Drug Delivery; 2019 02/11/19

Kang D., et al. Porcine Model to Evaluation Local Tissue Tolerability Associated with Subcutaneous Delivery of Protein; Journal of Pharmacological and Toxicological Methods; 2013 05/01/13

Kang D., et al. Recombinant Human Hyaluronidase PH20 (rHuPH20) Facilities Subcutaneous Infusions of Large Volumes of Immunoglobulin in a Swine Model; Drug Delivery and Translational Research; 2012 04/27/12

Bookbinder, L.H., et al. A Recombinant Human Enzyme for Enhanced Interstitial Transport of Therapeutics; Journal of Controlled Release; 2006 08/28/06

PEGPH20

Date Title

Cao, J., et al. Dynamic Contrast-Enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma; Clinical Cancer Research; 2018 12/26/18

Li, XM, et al. Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression; Clinical Cancer Research; 2018 07/03/18

Hingorani S.R., et al. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients with Untreated, Metastatic Pancreatic Ductal Adenocarcinoma; Journal of Clinical Oncology; 2018 02/01/18

Hingorani, S.R., et al. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer; Clinical Cancer Research; 2016 06/01/16

Manuel, E.R., et al. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled With Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors; Cancer Immunology Research; 2015 09/01/15

Singha, N.C., et al. Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy; Molecular Cancer Therapeutics; 2015 02/01/15

Kultti, A., et al. Therapeutic Targeting of Hyaluronan in the Tumor Stroma; Cancers; 2012 09/06/12

Jacobetz, M.A., et al. Hyaluronan Impairs Vascular Function and Drug Delivery in a Mouse Model of Pancreatic Cancer; Gut; 2013 03/30/12

Provenzano, P.P., et al. Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma; Cancer Cell; 2012 03/19/12

Thompson, C.B., et al. Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models; Molecular Cancer Therapeutics; 2010 11/01/10

Companion Diagnostic (CDx)

Date Title

Whatcott, C.J., et al. Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer; Clinical Cancer Research; 2015 08/01/15

Jadin, L., et al. Characterization of a Novel Recombinant Hyaluronan Binding Protein for Tissue Hyaluronan Detection; Journal of Histochemistry and Cytochemistry; 2014 06/02/14

Jiang, P., et al. Effective Targeting of the Tumor Microenvironment for Cancer Therapy; Anticancer Research; 2012 04/01/12

Other

Date Title

Bano F., et al. Single-Molecule Unbinding Forces between the Polysaccharide Hyaluronan and its Binding Proteins; Biophysical Journal; 2018 06/19/18

Useful Links

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

ENHANZE^® Drug Delivery Technology

PEGPH20

Companion Diagnostic (CDx)

Other

Useful Links

Contact Info

Office:

Recent News

Notice